

ForPatients

by Roche

Small Cell Lung Cancer Small Cell Lung Carcinoma

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02C)

Trial Status

Active, not recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT04665856 YO42373

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT04665856 YO42373

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years

Healthy Volunteers

No
